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Dear Editor 
We would like to provide additional information in response to the letter from Professor 
Osborn and Dr Walters in relation to our recent paper published in the BMJ describing 
the derivation and validation of QRISK3 [1]. Of the 10,561,100 patients in our QRISK3 
derivation and validation cohorts, 593,738 (5.62%) were coded as having severe mental 
illness. Our definition was based on a combination of the Quality and Outcomes 
Framework (QOF) definition of severe mental illness plus a subset of the codes from the 
QOF definition of depression (having excluded those codes indicating mild depression).  
Overall across both derivation and validation cohorts, we identified 110,798 patients 
(1.05% of 10,561,100) with a coded diagnosis of either schizophrenia, bipolar affective 
disorders or other psychoses, the remaining 482,940 (4.57%) having a coded diagnosis 
of depression which was either moderate or severe depression or not identified as mild. 
We based our definition of depression on Read codes indicating moderate or severe 
depression, for example severe depression, major depression, recurrent depression, 
psychotic depression, depressive disorder, endogenous depression. We think we should 
have made this clearer in Box 1 of the original paper. 
Overall, across the validation and derivation cohorts, we identified 52,128 patients 
(0.49% of 10,561,100) who were prescribed atypical antipsychotics at study entry. Of 
these, 35,452 (68.01%) had a diagnosis of severe mental illness (using the broader 
definition above) and of these, 24,394 (68.81%) had a diagnosis of bipolar affective 
disorders or schizophrenia. There were 16,676 (31.99%) of 52,128 patients on atypical 
antipsychotics, who did not have a recorded diagnosis of schizophrenia, bipolar affective 
disorders or moderate/severe depression. Most atypical antipsychotic drugs will be 
initiated in secondary care with the ongoing prescriptions generally issued by primary 
care.  
Stevens et al may have misinterpreted how we calculated the standard deviation of 
systolic blood pressure so we would like to clarify that. In our Methods section, we stated 
the following, “To assess variability in systolic blood pressure, we identified all systolic 
blood pressure values recorded in the five years before study entry and calculated the 
standard deviation where there were two or more recorded values”. Of those who had a 
standard deviation calculated, this was based on two values for 33.9% of patients and 
on three or more values for the remaining 66.1% of patients. So, if there were only two 
values, these would have been used but if there had been 20 values in the preceding five 
years for an individual patient, then all 20 would have been used to calculate the 
standard deviation. In other words, we used all the available values to calculate the 
standard deviation and in so doing, developed an approach which could be implemented 
back into the GP computer systems where all such values will be recorded. Regarding 
the number of imputations, because we calculated variability over 2 or more readings, 
we feel that 5 imputations remains a pragmatic choice in view of the volume of data 
(nearly 8 million patients in the derivation cohort). Given the magnitude and significance 
of the coefficients in our models any imputation variability will have little substantive 
impact on the precision of estimates and selection of variables based on tests of 
significance [2]. 
In our study, we reported an adjusted hazard ratio of 1.08 (95% CI 1.07 to 1.09) in 
women and 1.11 (1.09 to 1.12) in men associated with a 10-unit increase in standard 
deviation of systolic blood pressure. This is lower than that reported in the paper by 
Stevens et al [3] which was 1.18 (95% CI 1.07 to 1.30) but their hazard ratio relates to 
a standardised measure of systolic blood pressure variability on a different scale to our 
values (“blood pressure variability divided by its sample standard deviation”). Although 
Stevens et al undertook a meta-analysis for other outcomes, they were only able to 
identify a single eligible study for the cardiovascular disease outcome [4]. This study 
consisted of a highly selected group of 8811 patients with type 2 diabetes recruited to a 
clinical trial experiencing 404 cardiovascular events who are unlikely to be representative 
of the general population eligible for cardiovascular disease risk assessment. Their cohort 
was considerably older (mean age 66 compared with 43 in QRISK3) and had 
substantially higher systolic blood pressure values compared with the QRISK3 
population. For example, the mean systolic blood pressure was 137 mmHg compared 
with 123 mmHg in women and 129 mmHg in men in our study. Furthermore the blood 
pressure measurements in the trial were made at specific follow-up times using 
standardised equipment which does not reflect the situation in a primary care setting 
where the QRISK3 risk prediction models are intended to be used. 
Stevens et al correctly state that patients using antihypertensive medication were 
included in the cohort of patients used to develop QRISK3. The use of antihypertensive 
medication in patients with a diagnosis of hypertension was included as a parameter in 
the risk equation in a similar way to earlier versions of QRISK [5]. Given the purpose of 
QRISK3 (which is to assess CVD risk at a point in time based on information which is 
already available), we decided to assess each predictor at baseline based on information 
that was already available, not on information which might change at a future point. 
Whilst it would be possible to model changes in medication during follow up as a time 
varying exposure, it is conceptually difficult to see how such a risk equation could be 
used in clinical practice as the information would not be known to either the doctor or 
the patient at the time of assessment. This is also relevant to the interesting point that 
Peek et al make regarding interventions which may occur during follow-up.  
Stevens et al also highlight the similarities in the validation statistics between the 
models with and without the standard deviation of blood pressure. Whilst we felt that, on 
average the models had the same overall performance, for those patients that do have 
higher levels of blood pressure variability, it seemed reasonable to choose the model 
that could represent that increased risk to some degree. It is possible that the risk 
associated with blood pressure variability has been underestimated, but choosing a 
model without any variable for this, would lead to even more underestimation of the true 
risk in people with variable blood pressure. Further versions of QRISK3 could seek to 
improve how blood pressure variability is represented in the model. 
Lastly, whilst independent external validation of risk assessment tools is the gold 
standard, numerous validation studies of the QRISK2 cardiovascular risk prediction 
algorithms (including external studies) have shown that the results in our independent 
validation practices pretty much match the results when tested in other similar 
databases both in the UK [6-10] and internationally [11] [12]. We have no reason to 
think this study should be different but also look forward to future validation studies to 
confirm our results.  
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